A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Key Findings:  This study of patients with Fragile X syndrome found that a novel transdermal preparation of cannabidiol (ZYN002) was well tolerated and effective in reducing disruptive social behaviors in children and adolescents with  ≥ 90% methylation of the promoter region of the FMR1 gene.

Type of Study:  Double Blind Clinical Trial

Study Sample Size:  212

Study Result:  Positive

Study Location(s):  Australia, United States

Year of Pub:  2022

Cannabinoids Studied:  Cannabidiol (CBD), Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG)

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype III

Receptors Studied:  CB1, CB2, GPCR

Ligands Studied:  Dopamine, GABA, Serotonin

Dosage: ZYN002 (cannabidiol) - 250 mg or 500 mg transdermally, daily

Route of Administration:  Topical

Link to study